Introduction
Cushing's Syndrome refers to the clinical manifestations that result from excess levels of circulating steroid 1 .
Ectopic secretion of ACTH accounts for about 10% of cases of endogenous hypercortisolaemia [1] [2] . Lung tumours account for the vast majority of these 2 .
There are a small number of cases described of ACTH secretion from prostate cancer 2-4 , but we have not found any other cases of histologically confirmed prostatic adenocarcinoma with neuroendrocrine differentiation, which secreted clinically significant levels of ACTH. We present such a case in a 62-yearold man.
Case Report
 62 year-old male presenting with a two-week history of intermittent confusion, plethora and left arm weakness on a background of rapidly progressing metastatic prostate adenocarcinoma diagnosed eight months earlier. 
Investigation and management
Initial investigations: ECG -prolonged QT (550ms); BM -17.1 (previously non-diabetic); MRI spine -malignant root compression of C6 nerve root. Initial management: Aggressive potassium and magnesium replacement; Metyrapone and Ketoconazole started to treat hypercortisolaemia; anti-diabetic medications initiated; urgent oncology review and discussion at neuroendocrine MDT for further management.
PSA levels -ng/ml Histology Outcome
Once we introduced Metyrapone and Ketoconazole, our patient's cortisol was successfully suppressed -his potassium normalised, and his hyperglycaemia was brought under control.
We reviewed his histology, which was negative for retrospective ACTH staining. He was not biopsied again. We discussed his management extensively at neuroendocrine, oncology and endocrine surgery MDTs: he was not felt to be a candidate for surgical intervention. His chemotherapy was subsequently changed from conventional prostate cancer chemotherapy to Etoposide-Carboplatin; now in his sixth cycle, he continues to show a sustained partial response -his ACTH and PSA are suppressed and his spinal metastases have regressed.
The prolonged elevation of ACTH and associated high cortisols suppressed his HPA axis, and he now requires replacement hydrocortisone.
Discussion
To our knowledge, we present the first case of Cushing's Syndrome resulting from ectopic ACTH production arising from a prostatic adenocarcinoma with neuroendocrine differentiation. Whilst definitive management of Cushing's Syndrome secondary to ectopic ACTH production is surgical 4-6 (excision of primary tumour with neuroendocrine differentiation and/or bilateral adrenalectomy), our patient was successfully managed on medical therapy and then chemotherapy.
Crucial to his successful management was the immediate recognition of rapidly progressing hypercortisolaemia. In addition, the retrospective review of histology and subsequent effective MDT discussion enabled his oncology team to review his initial diagnosis and alter his chemotherapy regimen accordingly. Neuroendocrinology and pituitary
